Skye Bioscience, Inc. — Director's Dealing 2014

Dec 8, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2014-12-04

Reporting Person: Murphy Brian Stuart (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-12-04	Stock Option (Right to Buy)	$0.42	A	480000	Acquired	2024-10-31	Common Stock (480000)	Direct
2014-12-04	Stock Option (Right to Buy)	$0.42	A	175000	Acquired	2024-11-21	Common Stock (175000)	Direct

Footnotes

F1: The Board of Directors of the Company approved the grant of Stock Options on October 31, 2014, at an exercise price of fair market value. The Company engaged an independent third party to establish the fair market value on the date of grant. On December 4, 2014, the Board of Directors of the Company accepted the valuation report and set the exercise price at $0.42 per share.

F2: Reporting Person's right to receive Stock Options vest over a five year period, with the first 20% of the total Stock Options vesting on the one year anniversary of the grant date the remainder of the shares will vest in equal installments on a annual basis thereafter, such that the Stock Options are fully vested on October 31, 2019.

F3: The Board of Directors of the Company approved the grant of Stock Options on November 21, 2014, at an exercise price of fair market value. The Company engaged an independent third party to establish the fair market value on the date of grant. On December 4, 2014, the Board of Directors of the Company accepted the valuation report and set the exercise price at $0.42 per share.

F4: Reporting Person's right to receive Stock Options vest over a five year period, with the first 20% of the total Stock Options vesting on the one year anniversary of the grant date the remainder of the shares will vest in equal installments on a annual basis thereafter, such that the Stock Options are fully vested on November 21, 2019.